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Abstract
Fatigue is one of the most bothersome symptoms reported by patients diagnosed
with cancer, and research indicates that the majority of patients receiving chemotherapy
report symptoms of fatigue. Fatigue can have an effect on quality of life; therefore, it is
essential that healthcare providers gain a better understanding and recognition of fatigue.
Fatigue can also be a symptom of depression. Depression is another prominent
symptom reported by patients diagnosed with cancer. Unfortunately, there are similarities
between the symptoms of depression and fatigue making it difficult for health care
providers to distinguish between the two. This study utilizes the subscale of the Hospital
Anxiety and Depression Scale and the Multidimensional Fatigue Scale-Short Form to
further investigate the relationship between cancer-related fatigue and depression.
The convenience sample consisted of 30 chemotherapy patients being treated at an
outpatient infusion center in a comprehensive cancer center in southwest Florida. All
participants were between the ages of 26 and 74, and had been receiving chemotherapy
for a minimum of three weeks; none had been diagnosed with chronic fatigue syndrome,
or were currently being treated with radiation.
The participants in the study self-rated their fatigue on a Likert-type scale of 0-10.
The mean score on the self-rated fatigue scale was 4.03 (SD= 2.76). This study supports
prior studies in which chemotherapy patients report mild to severe levels of fatigue.
The mean score on the depression subscale of the Hospital Anxiety and
Depression subscale was 4.53 (SD=4.2). A statistically significant correlation was noted
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between cancer-related fatigue and depression, utilizing the Hospital Anxiety and
Depression subscale score and Multidimensional Fatigue Inventory–Short Form total
scores (r=.676, p=.000).
This study provides evidence that tools such as the Hospital Anxiety and
Depression Scale and the Multidimensional Fatigue Inventory-Short Form can aid
researchers and providers in distinguishing between fatigue and depression. Using these
instruments in future research and practice may help avoid the overlap in symptoms of
fatigue and depression.
These study results support findings from previous studies indicating a moderate
correlation between cancer-related fatigue and depression. This study addresses the
correlation between cancer-related fatigue and depression in chemotherapy patients
which may improve nursing assessment of fatigue and depression in this population.
Findings suggest the need for ongoing research focusing on cancer-related fatigue and
depression as well as appropriate pharmacological and non-pharmacological
interventions to improve the quality of life of this patient population.

v

Chapter I. Introduction
The American Cancer Society (2010) estimates that more than 1,529,560 people
will be diagnosed with cancer annually. Many patients diagnosed with cancer will be
treated with chemotherapy. Hauser, Walsh, Rybicki, and Seyidova-Khoshknabi (2008)
estimated that 90% of patients diagnosed with cancer, report cancer-related fatigue.
These numbers are significant to health care providers as more people are being
diagnosed with and surviving cancer. These persons present with multifaceted symptoms
that may be related to the diagnosis of cancer.
One of the most common distressing symptoms reported by patients with cancer
is fatigue. Mitchell and Berger (2006) report that 78% of patients with cancer report
living with the distressing symptom of fatigue. Cancer patients report fatigue during and
soon after cancer treatment has concluded. Fatigue is an important symptom for health
care providers to understand and assess as it impacts the patient with multifaceted
problems such as weakness, decreased mental concentration, insomnia or hypersomnia,
and emotional reactivity. These multifaceted problems could also be identified as
symptoms of depression. It is important for the provider to be able to distinguish between
cancer-related fatigue and depression as both have a negative effect on the patient.
Providers must realize the strong implications of fatigue and depression as both affect the
patient’s physical, social and vocational functioning, mood, and sleep disturbances as
well as affecting family members.
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It is important to make an accurate diagnosis of depression in the patient with
cancer as a misdiagnosis can have negative clinical consequences (Endicott, 1984). The
treatment for depression can increase the somatic symptoms if a misdiagnosis of
depression is made. Another consequence of misdiagnosing depression is that fatigue,
decreased energy, and change of appetite can be overlooked in the patient with cancer if
attributed to a depressive disorder instead of an underlying medical problem. A provider
can easily attribute the somatic symptoms associated with cancer and its treatment to
depression which can result in over diagnosis of depression (Walker et al., 2007).
Stress from a medical condition such as cancer can lead to somatic symptoms
seen also in depression. It can be difficult for a provider to distinguish depression from
cancer related symptoms. Jean-Pierre and colleagues, (2007) noted that there is a
significant challenge in distinguishing cancer-related fatigue from depression as the
measurement of these variables tends to overlap. It is important for the provider to use a
tool that would help accurately diagnose symptoms of depression. Zigmond and Snaith
(1983) worked to help providers distinguish between anxiety and depression by
developing the Hospital Anxiety and Depression Scale (HADS Scale), a tool which
assesses mood without including physical symptoms such as tiredness or lack of appetite.
Problem Statement
Numerous studies have been conducted on cancer-related fatigue and depression
as separate entities. Limited studies take into consideration the bias introduced by
depression measures that include fatigue as an item (Brown & Kroenke, 2009).
Chemotherapy is often associated with fatigue and depression. More research is needed
to determine whether cancer-related fatigue and depression are correlated using methods
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that avoid the overlap in symptoms of fatigue and depression. The purpose of this study
was to evaluate the relationship between cancer-related fatigue and depression in patients
receiving chemotherapy.
Research Questions
The following research questions are addressed in this study:
1. What is the mean fatigue severity in patients receiving chemotherapy based on the
Multidimensional Fatigue Symptom Inventory-Short Form?
2. What is the mean severity of depressive symptoms in patients receiving chemotherapy
based on the Hospital Anxiety and Depression Scale: Depression Subscale?
3. Is there a significant positive relationship between fatigue severity and severity of
depressive symptoms in patients receiving chemotherapy?
Definition of Terms
For the purpose of this study the following terms are defined:
Fatigue: “persistent and subjective sense of tiredness related to cancer or cancer
treatment that interferes with usual functioning” (Jean-Pierre et al., 2007, p.12).
Minor Depression: “individuals who experience at least two depressive
symptoms for two weeks but do not meet the criteria for major depression” (Fauci, 2008,
p.2716).
Major Depression: “individual who has a depressed mood on a daily basis for a
minimum duration of two weeks” (Fauci, 2008, p.2716).
Significance to Nursing
Cancer-related fatigue and depression are significant to nursing as each have an
impact on quality of life and possibly survival of patients. Nurses must assess for both
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fatigue and depression in an effort to provide holistic care to the chemotherapy patient.
Research has shown that cancer-related fatigue can last years past the final cancer
treatment; therefore early assessment and intervention are necessary.
This study may identify a correlation between cancer-related fatigue and
depression. Understanding the relationship between cancer-related fatigue and depression
may allow the nurse to offer appropriate interventions. Management of the symptom of
fatigue and depression can help improve the quality of life of the patient and perhaps
extend the life of the patient diagnosed with cancer and treated with chemotherapy.
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Chapter II. Review of Literature
The literature from 1983 to present was reviewed utilizing Ovid, PubMed,
CINAHL, and EBSCOhost electronic databases. Key terms used included a combination
of the following: fatigue, cancer, cancer-related fatigue, chemotherapy, depression and
cancer, depression and cancer-related fatigue. First, research pertaining to fatigue in
cancer is reviewed. Second, research focusing on fatigue and cancer is presented. Finally,
research relating fatigue and depression is reviewed. The chapter ends with a summary of
pertinent variables.
Fatigue in Cancer
Cancer-related fatigue is a symptom that is very disruptive in the life of the cancer
patient. It affects patients not only physically, but psychosocially as well, having an
impact on the overall quality of life of the patient. Cancer-related fatigue differs from
normal fatigue as it is not relieved by rest or sleep and persists over time becoming more
intense. This fatigue can last even after cancer treatment has concluded (Morrow, 2007).
Hofman, Ryan, Figueroa-Moseley, Jean-Pierre, and Morrow (2007) identified
how fatigue impacted patients with different cancer diagnoses. The researchers found that
more than 80% of patients receiving outpatient chemotherapy report fatigue as a
significant side effect of treatment. Patients diagnosed with melanoma, prostate, or lung
cancer had fatigue lasting more than six months which also affected their functional
abilities.
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This study provides evidence that cancer-related fatigue is a significant side effect
of chemotherapy treatment. Hofman and colleagues, (2007) surveyed 379 patients who
had chemotherapy treatment and 76% reported the side effect of cancer-related fatigue in
comparison to 54% who reported nausea, 23% who reported depression, and 20% who
reported pain. The researchers also found that 88% of patients who had chemotherapy
reported that fatigue had affected their activities of daily living.
Jean-Pierre and colleagues, (2007) found that a patient can reliably rate fatigue on
a scale from 0 to10 asking such questions such as, “ How would you rate your fatigue on
a scale of 0 to 10 over the past 7 days?” Scores were assigned numerically with a 0
indicating no fatigue, 1 to 3 mild fatigue not requiring intervention, 4 to 6 and 7 to 10 as
moderate and severe fatigue which would require further assessment and intervention.
These questions are subjective and are based on the patient’s personal experiences.
Hauser, Walsh, Rybicki, and Seyidova-Khoshknabi (2008) examined the affect of
fatigue in 171 patients with advanced cancer. The researchers created a fatigue
questionnaire to gather clinically significant information on cancer-related fatigue (CRF).
This tool evaluated fatigue at present and in the past week with the use of 100 mm visual
analog scales (VAS) with one end of the scale labeled as very fatigued and the other end
as no fatigue. This study showed a negative correlation between quality of life and
fatigue. Persons with lung cancer reported that the affect of fatigue on quality of life is
worse than the affects of dyspnea and pain. Researchers also noted that fatigue is related
to significant disability to perform daily activities and ability to enjoy relationships
(Hauser et al., 2008).

6

Prue, Rankin, Cramp, Allen, and Gracey (2006) investigated the
relationship of fatigue and gynecological cancer using the Multidimensional Fatigue
Symptom Inventory-Short Form (MFSI-SF). The researchers collected data from 30
female patients ranging from 31to 84 years of age. Data showed that 85% of participants
reported that tiredness had an affect on their ability to complete activities of daily living.
Nausea, vomiting, and pain were also symptoms reported by participants; however, these
symptoms did not affect activities of daily living. This study showed that 90% of
participants related fatigue to their cancer diagnosis.
Survivors of breast cancer commonly report fatigue as a distressing symptom
following adjuvant treatment lasting months to years. Fatigue has an affect on quality of
life; therefore, researchers worked to identify demographic, medical, and psychosocial
characteristics of 1,957 survivors (Bower et al., 2000). This study provided evidence that
there is no difference in level of fatigue in survivors who received different treatment
regimens including surgery, radiation, adjuvant chemotherapy, and Tamoxifen. Energy
levels remained low one year after treatment. The RAND scale provided evidence that
bodily pain is strongly associated with fatigue and is correlated with greater problems
with sleep and sleep disturbance. Researchers also found a strong correlation between
fatigue and depression. Researchers found the link between fatigue and depression to be
complex. Fatigue can be a symptom of depression or it can be associated with symptoms
of depression. This data provides evidence of the importance of screening for depression
and other disorders in cancer survivors who complain of fatigue.
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Depression in Patients with Cancer
It can be difficult for the provider caring for a patient with cancer to diagnose
depression when cancer-related fatigue is present because of the overlap in symptoms.
Evidence has shown that depression is one of the most significant problems experienced
by cancer patients. Reich (2008) reported that oncology patients who are depressed have
a higher relapse rate and decreased compliance with treatment.
Singer and colleagues, (2010) studied depression in oncology patients
incorporating the HADS. The researchers noted that the severity of the depression is not
related to the stage of the cancer but with socio-demographic and psychosocial
characteristics. The researchers identified that medical providers typically screen for
depression without use of a structured clinical interview tool. The goal of this study was
to provide evidence of the importance of implementing a screening tool for diagnosis of
depression. In this cross-sectional study of 329 patients, researchers used the HADS
questionnaire to identify participants with depression. Twenty-eight (11.75%) patients
were identified as having either major or minor depression. Furthermore, in this study the
HADS had a sensitivity of 96%. This study provides supportive evidence of
implementing a screening tool such as the HADS to help identify, early in the treatment
process, patients who may be depressed.
Castelli, Binaschi, Caldera, Mussa, and Torta (2010) conducted a study of 151
subjects newly diagnosed with different cancer pathologies. In this study the researchers
provided evidence that a cut off score of eight, instead of eleven, is more accurate in
screening for depression when using the HADS. The results of this study also provide
evidence of the prevalence of depression in newly diagnosed cancer patients. This study
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showed that the HADS can be used in practice to quickly and accurately screen for
depression in patients diagnosed with cancer. Krespi-Boothby and colleagues, (2010) also
provide evidence that the HADS tool accurately detected major depression as defined by
the Diagnostic and Statistical Manual of Mental Disorders (DSM) when a cut off score
of eight is used. The investigators used the HADS scale in screening 251 patients
diagnosed with breast cancer.
Castelli, Binaschim, Caldera, and Torta (2009) recognized the importance of
screening for depression in outpatients receiving treatment for cancer. The researchers
conducted a study of 53 newly diagnosed lung cancer patients, who had been advised to
undergo chemotherapy, to determine the accuracy of the HADS scale in screening for
depression. Results showed that the HADS is a fast and accurate screening tool for
depression when a cut off score of eight is used. The study also shows evidence of the
high prevalence of depression in newly diagnosed lung cancer outpatients (Castelli,
Binaschim, Caldera, & Torta, 2009).
The Relationship between Fatigue and Depression in Cancer
Cancer-related fatigue is one of the most common symptoms reported by patients
undergoing cancer treatment that is often unrelieved. This fatigue can have an effect on
quality of life affecting physiological, psychological, and behavioral aspects (Goldstein et
al., 2006). Fatigue is reported with many medical and psychological conditions including
major depression. Fatigue continues to be ongoing in over 75% of patients after treatment
is completed. Goldstein and colleagues, (2006) hypothesized that fatigue will vary in the
presence of other variables, such as psychological symptoms, and that most cases will
improve over time.
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Two-hundred and twelve women ages 26 to 85 who were treated for stage one or
two breast cancer were asked to participate in the study if they had adjuvant treatment in
the last twelve months. Researchers used the Somatic and Psychological Health Report
(SPHERE) questionnaire to screen for any significant fatigue states and mood disorders
(Goldstein et al., 2006). The SPHERE tool assesses somatic and psychological
symptoms, assessment of fatigue following infectious illness, and in patients following
adjuvant treatment for cancer. The Brief Disability Questionnaire was also used by
researchers to determine social and occupational role impairment due to fatigue.
Data from this study showed that 48% of the subjects reported clinically
significant fatigue; 36% reported depression or anxiety and 81% of those were also cases
of fatigue (Goldstein et al., 2006). Further data shows that functional status is impaired
in persons with fatigue who reported difficulty walking up stairs (40%) whereas those
who did not report fatigue only 10% reported difficulty walking up stairs. The researchers
found 48% of subjects had a significant fatigue state post cancer treatment, and 33%
reported significant psychological distress. Only 1% of cases were found to be solely
fatigue, with no accompanying psychological disorder whereas 52% of cases were found
to have both disorders. Goldstein and colleagues, (2006) found that psychological
distress was the only risk factor associated with post-cancer fatigue (p<0.00001).
This study provides evidence of the prolonged effect of cancer-related fatigue.
Evidence from the study shows that fatigue lasts beyond the end of cancer treatment as
long as 48 months. Prior studies have shown that fatigue can last up to ten years post
cancer treatment (Goldstein et al., 2006). The SPHERE tool is beneficial in showing the
correlation of poor mental health and fatigue. This study also provides evidence that
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fatigue is not related to a mood disorder such as depression. The study does, however,
indicate the relationship of fatigue and mood disorders in the majority of the cases, and
both problems are sustained over time.
Jean-Pierre and colleagues, (2007) noted that there is a significant challenge in
distinguishing cancer-related fatigue from depression as the measures of each variable
correlate highly. In a study of 724 cancer patients, one week after completing
chemotherapy, there was an overlap identified in depression and fatigue in multi-item
measures of fatigue. Questions such as “to what degree have you experienced fatigue in
the past week?” were found to have a high correlation on multi-item and single-item
measures of fatigue and depression.
It is important that providers not only recognize the symptom of cancer-related
fatigue but know how to assess it as well. Jean-Pierre and colleagues, (2007) provide
evidence that unidimensional and multidimensional measurements of CRF are both
reliable scales to assess cancer-related fatigue. More importantly the researchers found
that the unidimensional scale for fatigue is just as reliable and valid as a more complex
multidimensional tool. The researchers also showed that patients are capable of selfreporting cancer-related fatigue and can reliably complete questionnaires which ask
subjective questions on cancer-related fatigue. It is important however for the provider to
remember the strong correlation between fatigue and depression when measuring on both
single and multi-item scales.
The patient diagnosed with cancer not only has to cope with the disease but with
the multiple symptoms associated with the disease and with its treatment. Barsevick and
colleagues, (2006) recognized the symptoms of fatigue and depression in cancer patients.
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The researchers tested a hypothesis about the direct and indirect relationships between
fatigue and depressive symptoms and functional status. Previous studies have shown a
relationship of symptom clusters showing that one symptom can influence another
symptom, and even affect a third symptom (Barsevick et al., 2006).
Researchers conducted a clinical trial of 396 patients being treated for different
forms of cancer including breast, gynecologic, testicular, lung, advanced prostate cancer,
or lymphoma. Persons with a diagnosis of anemia, or having a psychiatric disorder, or
treatment for depression in the last three weeks were excluded from this study. Data was
collected from all subjects at times noted to be correlated with highest levels of fatigue in
both the chemotherapy and radiation group. Subjects were assigned to intervention
groups either, energy conservation and activity management, or a control intervention
consisting of information on a healthy diet (Barsevick et al., 2006). A secondary analysis
was conducted by the researchers to determine direct and indirect relationships between
fatigue and depressive symptoms. These investigators hypothesized that fatigue would
influence depressive symptoms and that as fatigue increased functional status was
expected to worsen which would cause an increase in depressive symptoms.
Researchers found that functional status after cancer therapy affected the
relationship between fatigue and depressive symptoms (Barsevick et al., 2006).
Researchers found that when functional status was controlled, the relationship between
fatigue and depressive symptoms was reduced (p<.001). For the energy conservation and
activity management group fatigue was found to be associated with depressive symptoms
and related to functional status. In this group the intervention changed the role of
functional status but did not reduce fatigue and depressive symptoms.
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This study shows the correlation of fatigue and depression and its effect on
functional status. This study provides further evidence of the correlation of fatigue and
depressive symptoms. This research shows that changing functional status can have an
affect on fatigue and symptoms of depression. Barsevick and colleagues, (2006)
reinforced that fatigue is an expected symptom in cancer patients and can be correlated
with depression.
Summary
Cancer-related fatigue is one of the most common symptoms experienced by
chemotherapy patients; yet health care providers may offer no assessment or intervention
to help improve the symptoms of fatigue or depression which may affect the quality of
life of the chemotherapy patient. The review of literature provided evidence of the
correlation of cancer-related fatigue and depression. Jean-Pierre and colleagues, (2007)
noted that there is a significant challenge in distinguishing cancer-related fatigue from
depression as the measures of each variable correlate highly. The research by Barsevick
and colleagues, (2006) provides evidence of the direct and indirect relationships between
fatigue and depression symptoms. Goldstein and colleagues, (2006) provide evidence that
fatigue lasts up to 48 months after cancer treatment has concluded. The aim of this study
is to further evaluate the correlation of cancer-related fatigue and depression in patients
undergoing chemotherapy treatment by methods that avoid the overlap in symptoms of
fatigue and depression.
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Chapter III. Methods
The purpose of this study is to determine whether there is a significant
relationship between cancer-related fatigue and depression in cancer patients receiving
chemotherapy. This chapter outlines the research methods. First the sample and setting
are described. The instruments included in the study are then discussed. Then, data
collection procedures are outlined, and finally, data analysis information is provided.
Setting and Sample
The sample consisted of patients from Moffitt Cancer Center Infusion Center
currently undergoing chemotherapy treatments. To achieve adequate power (.80) for a
moderate effect size, with alpha set at .05, a sample of 60 was needed.
For inclusion in the study, the patients had completed any prior chemotherapy
regimen for a minimum of three weeks prior, were receiving chemotherapy treatment
lasting longer than two hours, had any cancer diagnosis, were at least 18 years of age,
male or female, and were able to speak, read, and write English. Those who were
undergoing their first chemotherapy treatment were excluded, as was any patient
currently on antidepressant therapy, or with a history of chronic fatigue syndrome. Any
patient whose treatment time was less than two hours was excluded from the study.
Instruments
The Hospital Anxiety and Depression Scale. The work by Zigmond and Snaith
(1983) provides evidence that the HADS Scale (Appendix A) is a reliable instrument that
can be used to screen for anxiety and depression in a non-psychiatric setting. Research
14

also demonstrated that this scale is reliable for assessing severity of depression and can
be used on multiple occasions to determine patient progress. This scale encourages the
removal of somatic symptoms such as insomnia, fatigue, and pessimism about the future
when diagnosing depression. Zigmond and Snaith (1983) found that once they removed
the emotional and somatic illness, then the results of the scale were not affected by
physical illness. This scale is useful in assessing the presence or absence of depression
and its severity in the patient diagnosed with cancer as it removes the somatic symptoms
enabling the provider to make a more accurate and confident diagnosis.
The Hospital Anxiety and Depression Scale (HADS) is a screening tool which
assesses depression (Zigmond & Snaith, 1983). This instrument was chosen because it is
a simple tool which allows for screening of depression symptoms over the past week. The
HADS also excludes somatic symptoms, which could be attributed to cancer and its
treatment (Walker et al., 2006). There are a total of seven items pertaining to symptoms
associated with depression. It is a four-point Likert–type scale ranging from zero to three,
with varying response categories, which applies to the previous week. For the depression
subscale, a score ranging from 0 to 21 is calculated: scores less than eight are deemed
“non-cases”. Scores of eight, nine, ten are rated borderline; and scores of eleven or more
are indicative of the probable presence of psychological distress. The questionnaire is
written on a seventh grade reading level, can be self-administered, and takes three to five
minutes to complete (Walker et al., 2006).
Reliability. Reliability of the depression subscale was tested with a 1% false
positive, 1% false negative whereas the anxiety subscale had a 5% false positive and 1%
false negative. Researchers then determined that the findings of both the anxiety and
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depression subscales could be used to indicate the severity of depression and anxiety
(p<0.001). The researchers also found that the subscale scores of anxiety and depression
were not affected by physical illness.
Alpha coefficients for the depression subscale of the HADS is 0.86 (Olsson,
Mykletun, & Dahl, 2005). A study by Walker and colleagues, (2007) found that the
HADS tool was reliable when used as a screening tool for depression in mixed cancer
outpatients. The depression subscale of the HADS had a sensitivity of 0.90 (95% CI,
0.74-0.97) with a specificity of 0.88 (95% CI, 0.84-0.91) (Walker et al., 2007).
Validity. Walker and colleagues, (2007) compared the HADS specifically to the
Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). The
researchers found when using the HADS total score to identify cases of major depressive
disorder (MDD) the area under the receiver operating characteristic (ROC) curve was
0.94. Walker and colleagues, (2007) found that when screening for MDD in cancer
patients a cut-off score of ≥15 to be optimal with a 95% CI, (0.70-0.95) and a specificity
of 0.85(95% CI, 0.81-0.89). This reduces misclassifications of MDD at 0.65 for true
negative cases and 0.01 for true positive cases. The study by Walker and colleagues,
(2007) validated that the HADS tool is an adequate screening tool for major depressive
disorder in mixed cancer outpatients with the areas under the ROC curve close to 1.00
which indicate a good overall performance and good levels of sensitivity and specificity.
Multidimensional Fatigue Symptom Inventory-Short Form. The
Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) is a Likert-type
scale consisting of 30 questions (Jean-Pierre et al., 2007). The MFSI-SF instrument
(Appendix B) was chosen as it has been validated in patients with cancer and does not
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assume the presence of fatigue. This scale, like the HADS scale, inquires about patients
symptoms over the past week. This instrument consists of 5 subscales: general fatigue,
physical fatigue, emotional fatigue, mental fatigue and vigor (Stein, Jacobsen, Blanchard,
& Thors, 2004). Possible responses to the 30 questions assessing fatigue include 0=not at
all, 1= a little, 2= moderately, 3=quite a bit, 4=extremely. Higher scores indicate a higher
level of fatigue.
Reliability. Reliability was evaluated with internal consistency coefficients. The
alpha coefficients were 0.85-0.96 (Stein et al., 2004).
Validity. Construct validity of the MFSI-SF was determined by correlating the
instrument with the Fatigue Symptom Inventory (FSI) and the SF-36 Vitality Scale [r= 0.21 to 0.82] (Stein et al., 2004). Researchers found correlations among the five
subscales of the MFSI-SF and two measures of fatigue demonstrated excellent concurrent
validity, whereas correlations with a measure of physical well-being provided support for
convergent validity [r= 0.50-0.65] (Lin et al., 2009).
Demographic Data Form. The demographic data form (Appendix C) was
developed to describe the sample. Age, gender, and type of cancer are data included on
the form.
Procedures
Approval for the study was first requested from the Scientific Review Committee
at Moffitt Cancer Center & Research Institute (Appendix D). Following approval by the
Moffitt Committee, the proposal was submitted next to the University of South Florida
Institutional Review Board (Appendix E). Following approval the investigator began
accruing patients for the study.
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The investigator went to the Infusion Center at Moffitt Cancer & Research
Institute and introduced herself to patients at the infusion center and explained the
purpose of the study. Privacy was maintained during the interview by speaking with the
patients in their individual treatment bays of the infusion center. The investigator
answered any questions and if the patient chose to participate in the study, verbal consent
(Appendix F) was obtained, with a copy of the consent form given to the patient. The
investigator kept a record of how many patients were approached to participate in the
study, how many patients consented, and how many patients refused to participate.
Eligibility was confirmed prior to consent. The investigator asked the patient for
demographic data as she did not access the patient’s chart. A unique numbering system
was used. The questionnaires were completed by the patients while they were receiving
chemotherapy. Each subject was asked to complete the HADS and the MFSI-SF one time
while receiving chemotherapy on the day of data collection. The investigator remained
with the patients to answer questions while the forms were being completed. If patients
were unable to write because of weakness, or an intravenous line in the arm, the
investigator completed the forms by interviewing the patients. All data was stored in a
locked file cabinet. The investigator assumes that subjects responded truthfully to
questions.
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Data Analysis
Demographic data was analyzed to describe the sample. Frequencies, percentages,
means and standard deviations were used to analyze these data. Data was analyzed with
means and standard deviations to answer the following research questions:
1. What is the mean fatigue severity in patients receiving chemotherapy based on the
Multidimensional Fatigue Symptom Inventory-Short Form?
2. What is the mean severity of depressive symptoms of patients receiving chemotherapy
based on the Hospital Anxiety and Depression Scale: Depression Subscale?
Research Question three was:
3. Is there a significant positive relationship between fatigue and severity and severity of
depressive symptoms in patients receiving chemotherapy? A series of Pearson
correlation coefficients were reported.
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Chapter IV. Results, Discussion, and Conclusions
This chapter presents the findings of the study. Included in this chapter are the
study results, discussion of the results, conclusions, and suggestions for future research.
Results
Demographic Data. Forty–two patients were approached and 30 enrolled and
completed the study. The following are reasons for exclusion: two patients refused to
participate, four were currently on antidepressant therapy, five had been receiving
treatment less than three weeks, and one was currently receiving radiation. The sample
consisted of 30 participants, 18 male and 12 female, ranging in age from 26 to 74 with a
mean age of 59.5 (SD=12.4). The largest number of participants reported the following
cancer diagnoses: gastrointestinal (29.9%), gynecological (20%), genitourinary cancer
(19.9%), hematologic cancer (13.2%), and thoracic (9.9%) (Table 1). All participants had
been receiving chemotherapy for a minimum of three weeks; none had been diagnosed
with chronic fatigue syndrome, or were currently being treated with radiation.
Descriptive Data. On the demographic data form, participants self-rated their
current levels of fatigue on a scale of 0 to 10 (No Fatigue-Worst Fatigue) with a mean of
4.03 (SD=2.76) (Table 2), indicating a moderate level of fatigue. The Multidimensional
Fatigue Symptom Inventory–Short Form (MFSI-SF) was used to measure participants’
fatigue. The mean score for the total scale on MFSI-SF was 14.8 (SD=22.1) and patient
scores ranged from -20.00 to 62.00. Since scores may range from 0 to 96 with higher
scores indicating more severe fatigue, participants in this study reported low levels of
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fatigue. Subscales were further analyzed to determine the various types of fatigue (Table
3).
Table 1 Frequency and Percent of Reported Cancer Diagnosis
Type of Cancer

Frequency

Percent

Gastrointestinal

9

29.9

Gynecological

6

20.0

Genitourinary

6

19.9

Hematologic

4

13.2

Thoracic

3

9.9

Head and Neck

2

6.6

Table 2 Frequency and Percent of Participants’ Perceived Fatigue Based on 0-10 Scale
Fatigue Variable

Frequency

Percent

None (0)

3

10

Mild (1-3)

10

33.3

Moderate (4-6)

9

30

Severe (7-10)

8

26.7

Depression was assessed using the Hospital Anxiety and Depression Scale
(HADS). The mean score on the HADS was 4.53 (SD = 4.2) and scores ranged from 0-17
(Table 4). A score of seven or less on the depression subscale indicates a non-case of
depression; scores of 8 to10 indicate a borderline case of depression, whereas a score of
11 or more is indicative of a more probable case of depression. In this study, four
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participants’ scores indicated borderline cases of depression, and three indicated probable
cases of depression (Table 4).
Table 3 Means and Standard Deviations for Subscales of MFSI-SF
Subscale

Mean

Standard Deviation

General Scale Score

10.2

6.9

Physical Scale Score

5.7

5.7

Emotional Scale Score

5.2

5.1

Mental State Score

5.4

4.1

Vigor Scale Score

11.6

5.6

Total Scale Score

14.8

22.1

Table 4 Frequency and Percent of Participants’ HADS Depression Subscale Scores
Depression

Frequency

Percent

Non-Depression

23

76.6

Borderline

4

13.3

Probable

3

9.9

Correlations. Subscales were further analyzed using Pearson Correlations to
determine the relationship between cancer-related fatigue and depression (Table 5). A
statistically significant correlation was found between cancer-related fatigue and
depression utilizing the HADS Depression scores and MFSI-SF total scores (r=.676,
p=.000).
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General fatigue was assessed to further analyze both physical and psychological
aspects of fatigue. Mental fatigue was assessed to further analyze cognitive functioning,
including difficulty concentrating. Physical fatigue was assessed to analyze physical
sensations related to fatigue. Emotional fatigue was assessed to further analyze reduced
activity due to the influence of physical and psychological factors on activity. Vigor was
assessed to further determine how reduced motivation related to lack of motivation in
starting any activity, with a negative correlation noted. Focusing on MFSI-SF subscale
scores, all correlations with HADS Depression subscale scores were significant except
the mental and physical fatigue scale scores (Table 5).
Table 5 Correlation Between Cancer-Related Fatigue and Depression
Scale

HADS Depression Scores
r

p

Fatigue

.379

.039

General Scale Score

.594

.001

Physical Scale Score

.345

.062

Emotional Scale Score

.719

.000

Mental State Score

.344

.062

Vigor Scale Score

-.659

.000

Total Scale Score

.676

.000

Discussion
Demographic Data. A limitation of the study was the small sample size.
However, in spite of the small sample, significant relationships were found between
fatigue and depression. The age range of patients participating in the study was 26 to 74
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years of age with a mean age of 59.5, which is similar to earlier studies of cancer patients
(Delgado-Guay et al., 2008).The sample was mostly Caucasian with few Hispanics and
African American subjects. This also is a limitation of the study.
Another limitation of this study is the inclusion of different types of cancer which
can contribute to fatigue or depression. For example, pancreatic tumors can be associated
with depressive disorders due to the secretion of neuropeptides and neurohoromones in
addition to the secretion of growth hormones. Interferons and Interleukines used to treat
renal cell cancer, melanoma, and chronic myelogenous leukemia have been associated
with fatigue and depression (Jacobsen, Donovan, & Weitzner, 2003). Data from the
participants’ medical records was not available so it was not possible to evaluate possible
relationships between medical treatment and cancer-related fatigue and depression.
A cross-sectional study was conducted from February through March 2011.
Future research should include a longitudinal study perhaps following the participants
from early diagnosis through treatment to identify when the fatigue and/ or depression
symptoms begin and to correlate with treatment. This is of importance as Laugsand and
colleagues, (2010) noted that providers underestimated fatigue and depression. Patients
rated their own fatigue and depression symptoms higher than their health care providers
did. Patients rated fatigue on a scale of 0 to 100 as a 71 while their providers rated it as
54 and rated depression as 31 while their providers rated depression as 17 (Laugsand et
al., 2010). Participants in this study rated their own level of fatigue on a scale of 0 to 10
on the demographic data form for further comparison of results and correlations with the
instruments used in the study.
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Another limitation of this study is the reliability of data. Many participants were
unable to recall the number of treatments they had received or the origin of their cancer
prior to metastasis. Participants also were concerned about the stigma of depression;
therefore, future studies should use test-retest to ensure reliability of results.
Depression. Depression was assessed using the depression subscale of the
Hospital Anxiety and Depression Scale. An advantage of the HADS scale noted by
researchers it that its subscales do not include any physical symptoms that could interfere
with the measurement of fatigue (Brown & Kroenke, 2009). The mean score on the
HADS was 4.53 (SD =4.2). Twenty- three percent of participants scored eight or higher
on the HADS indicating possible case of depression. Pirl (2004) noted that major
depressive disorder affects 10 to 25 % of cancer patients. Walker and colleagues, (2007)
noted when using the depression subscale of the HADS to identify cases of depression
that a cut-off of ≥7 is optimal (95% CI, 0.74-0.97). Walker and colleagues, (2007) also
noted that the HADS depression subscale is an adequate screening tool for mixed cancer
outpatients as were used in this study. More significant findings may have resulted from
a larger sample size. Many participants verbalized concern over being labeled as
depressed; therefore the results may have been skewed due to patient bias.
Karakoyun-Celik and colleagues, (2009) noted that socio-demographic features
such as income, age, martial status, and education may significantly affect depression
levels. Income and education were not assessed in this study and no correlations were
calculated between age and marital status with either depression or fatigue, which is a
limitation of this study.
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Fatigue. The results of this study confirm that the majority of patients receiving
chemotherapy report fatigue (90%) with 57.7% rating fatigue as ≥3 on a scale of 0 to 10.
Similar findings by Hwang and colleagues, (2003) have previously been reported with
80% of chemotherapy patients reporting fatigue and rating fatigue as ≥3.
An advantage of the MFSI-SF is the instrument does not assume the presence of
fatigue and evaluates participants fatigue over a one week time frame (Stein, Martin,
Hann, & Jacobsen, 1998). The mean total score on the MFSI-SF was 22.1 (SD=14.8).
Hofman and colleagues, (2007) report that cancer-related fatigue rates vary depending on
the type of cancer from 37 to 78% for patients with lung cancer and 28-91% in breast
cancer, and 15% in those with prostate cancer. The researchers further noted that the
severity of cancer-related fatigue peaks within four or five days of completion of
treatment. Stein and colleagues, (2004) noted that the MFSI-SF is a valuable tool for
multidimensional assessment of cancer-related fatigue following the fourth cycle of
chemotherapy for mixed cancer diagnosis.
Correlations. The American Psychiatric Association’s Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV) refers to assessing a major depressive disorder by
having the presence of four or more symptoms in a two week period in addition to a
depressed mood or loss of interest in pleasure in usual activities. Fatigue and loss of
energy are also symptoms of depression according to the DSM-IV (Jacobsen, Donovan,
& Weitzner, 2003). In this present study participants self-rated their perceived level of
fatigue on a 0 to 10 scale which showed a significant correlation between cancer-related
fatigue and depression (r=.379, p=.039). Browne and Kroenke (2009) noted the average
correlation between fatigue and depression was 0.56 (95% CI: 0.54-0.58). Next, the
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total scores of the MFSI-SF were analyzed which showed a significant correlation
between cancer-related fatigue and depression (r=.676, p=.000). To further evaluate
relationships between cancer-related fatigue and depression, the MFSI-subscales were
analyzed. The MFSI consists of five subscales: general fatigue, physical fatigue,
emotional, fatigue, mental fatigue, and vigor. Jacobsen and colleagues, (2003) found a
significant correlation between cancer-related fatigue and depression in chemotherapy
patients. Prior studies have noted an overlap in symptoms of fatigue and depression in
cancer patients; this study used instruments which eliminate the overlap in symptoms and
allow for correlation of cancer-related fatigue and depression.
Using the MFSI-SF allows the researcher to focus on specific types of fatigue
such as emotional fatigue. The MFSI-SF asks the participant specific questions which can
be correlated with depression such as: “I feel upset, I feel nervous, I feel sad, I feel
depressed, I feel tense, and I feel distressed”. Emotional fatigue has been defined in prior
research as reduced activity due to the influence of physical and psychological factors on
activity. In this study the emotional fatigue subscale strongly correlated with depression
(r=.719, p=.000).
Implications for Nursing. The findings of this study have several implications
for nursing. This study supports prior research findings that there is a significant
correlation between cancer-related fatigue and depression even with physical indicators
of depression eliminated from the scale. Prior research has shown an overlap in
symptoms of fatigue and depression in chemotherapy patients.
Assessment of depression and fatigue in chemotherapy patients should be
emphasized in oncology nursing. Research has shown that providers inaccurately assess
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levels of depression and fatigue in oncology patients (Laugsand et al., 2010). It is
essential that assessment and intervention be incorporated into oncology nursing
curriculum.
There are no current tools for assessing both fatigue and depression. Currently,
researchers are assessing each independently using separate tools and then making
correlations. Nursing research should focus on developing a tool to assess both fatigue
and depression to reduce patient burden. Further nursing research is needed.
Conclusions
There is a significant, moderately strong relationship between cancer-related
fatigue and depression. This study with a small sample size consisted of a mixed cancer
population in an outpatient infusion center. This study supports prior studies which show
a significant correlation between cancer-related fatigue and depression; however, there is
limited research which focuses on assessment and intervention.
Recommendations for Future Research. Future studies should include a larger
sample size, with greater geographic diversity. More studies should focus on determining
when the fatigue or depression began to strengthen the correlation between fatigue and
depression. Both fatigue and depression have an impact on quality of life; therefore, it is
essential that future research focus on development of assessment tools and interventions.
Studies should also focus on specific tumors such as pancreatic tumors to correlate with
depressive disorders and fatigue. Depression and fatigue in this population can strongly
affect quality of life; therefore, it is essential that research continues so providers can
successfully assess and intervene to improve the quality of life chemotherapy patients.
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Appendix A: The Hospital Anxiety and Depression Scale: Depression Subscale
The Hospital Anxiety and Depression Scale (Zigmond and Snaith, 1983)
Read each item and circle the reply which comes closest to how you have been feeling in
the past week.
Don’t take too long over your replies; your immediate reaction to each item will probably
be more accurate than a long thought out response.
1. I still enjoy the things I used to enjoy:
Definitely as much
Not quite so much
Only a little
Hardly at all

0
1
2
3

2. I can laugh and see the funny side of things:
As much as I always could
0
Not quite so much now
1
Definitely not so much now
2
Not at all
3
3. I feel cheerful:
Not at all
Not often
Sometimes
Most of the time

3
2
1
0

4. I feel as if I am slowed down:
Nearly all the time
Very often
Sometimes
Not at all

3
2
1
0
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5. I have lost interest in my appearance:
Definitely
I don’t take so much care as I should
I may not take as much care
I take just as much care as ever

3
2
1
0

6. I look forward with enjoyment to things:
As much as ever I did
0
Rather less than I used to
1
Definitely less than I used to
2
Hardly at all
3

7. I can enjoy a good book or radio or TV program:
Often
0
Sometimes
1
Not often
2
Very Seldom
3
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Appendix B: The Multidimensional Fatigue Symptom Inventory –Short Form
The Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF)
(Stein, Jacobsen, Blanchard, & Thors, 2004)
Below is a list of statements that describe how people sometimes feel. Please read each
item carefully, then circle the one number next to each item which best describes how
true each statement has been for you in the past seven days.
Not at
A little
Moderately Quite a
Extremely
all
bit
1.
I have
0
1
2
3
4
trouble
remembering
things
2.

My muscles
ache

0

1

2

3

4

3.

I feel upset

0

1

2

3

4

4.

My legs feel
weak

0

1

2

3

4

5.

I feel
cheerful

0

1

2

3

4

6.

My head
feels heavy

0

1

2

3

4

7.

I feel lively

0

1

2

3

4

8.

I feel
nervous

0

1

2

3

4

9.

I feel relaxed 0

1

2

3

4

10.

I feel pooped 0

1

2

3

4

11.

I am
confused

0

1

2

3

4

12.

I am worn
out

0

1

2

3

4

13.

I feel sad

0

1

2

3

4
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14.

I feel
fatigued

0

1

2

3

4

15.

I have
trouble
paying
attention

0

1

2

3

4

16.

My arms feel 0
weak

1

2

3

4

17.

I feel
sluggish

0

1

2

3

4

18.

I feel run
down

0

1

2

3

4

19.

I ache all
over

0

1

2

3

4

20.

I am unable
to
concentrate

0

1

2

3

4

21.

I feel
depressed

0

1

2

3

4

22.

I feel
refreshed

0

1

2

3

4

23.

I feel tense

0

1

2

3

4

24.

I feel
energetic

0

1

2

3

4

25.

I make more
mistakes
than usual

0

1

2

3

4

26.

My body
feels heavy
all over

0

1

2

3

4

27.

I am

0

1

2

3

4
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forgetful
28.

I feel tired

0

1

2

3

4

29.

I feel calm

0

1

2

3

4

30.

I am
distressed

0

1

2

3

4

Administration and Scoring:
The MSFI-SF can be completed in a wide variety of settings in about 5 minutes. Items
are rated on a 5-point scale indicating how true each statement was for the respondent
during the last week (0 = Not all; 4 = extremely). Scoring instructions for the MFSI-SF
are as follows:
1. General scale score = sum of items 10, 12, 14, 17, 18, and 28
2. Physical scale score = sum of items 2, 4, 6, 16, 19, and 26
3. Emotional scale score = sum of items 3, 8, 13, 21, 23, and 30
4. Mental state score = sum of items 1, 11, 15, 20, 25, and 27
5. Vigor scale score = sum of items 5, 7, 9, 22, 24, and 29
6. Total scale score = sum of scales 1-4 minus the Vigor scale score
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Appendix C: Demographic Data Form

1. What is your current age? ____
2. Which gender are you? (Circle one) male/female
3. What type of cancer are you being treated for (breast, colon, lymphoma,
etc.)?________________________________________________________________
4. What do you understand the goal of the chemotherapy is (check one answer below)?
____cure
____prevention of recurrence
____slowing down the growth of the cancer
____relief of symptoms
____not sure
5. How many chemotherapy treatments have you had, not including today?_________
6. Have you ever been diagnosed with chronic fatigue syndrome? (Circle one) yes/no
7. Are you currently taking any antidepressant medication? (Circle one) yes/no
7a. Did you begin taking antidepressant medication before or after your cancer diagnosis?
(Circle one) Before/After
8. Marital Status (check one).
____Single
____Married
____Divorced
____Separated
____Widowed
9. On the scale below circle the number that corresponds with your current level of
fatigue.
No fatigue
The Worst Fatigue
0 1 2 3 4 5 6 7 8 9 10
10. Are you currently being treated with radiation? (Circle one) yes/no
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Appendix D: Moffitt SRC Approval

December 15, 2010

Gloria Guess, RN, BSN
H. Lee Moffitt Cancer Center & Research Institute
University of South Florida
12902 Magnolia Drive
Tampa, FL 33612
Dear Ms. Guess:
The Behavioral Subcommittee of the Scientific Review Committee (SRC)
has reviewed your response for your research protocol entitled,
“Correlation of Cancer-Related Fatigue and Depression: a Pilot Study”
(MCC16520).
The revised protocol version dated 12/10/10 is approved as written for use
at the Moffitt Cancer Center pending approval of the Institutional Review
Board (IRB) and satisfaction of institutional operational and financial review
requirements.
Please be aware that after you receive IRB approval, you must request study
activation before you commence any study activities. The Protocol Review
and Monitoring System will ensure that all applicable institutional reviews have
been completed. You will then be issued an activation letter. Upon receipt of
the activation letter, you will be able to conduct your study. Please contact
Diane Martinez, Manager, Protocol Support Office, at 813-745-8349 to request
study activation.
It is your responsibility to ensure that all Moffitt staff (nursing, pharmacy, data
management, etc.) are informed and aware of the details of the project. The
committee encourages the use of in-services for those projects that are
complex or require special attention.
All changes made to protocols approved by the SRC must be submitted to
the Protocol Review and Monitoring System office. Changes made to the
protocol document require SRC review and approval. Minor changes (i.e.
changes to personnel, non-scientific changes, changes that do not affect
patient participation) will be expedited through the SRC review process.
If this project is not being managed by the Clinical Trials Office or Clinical
Research Unit, then it is your responsibility to follow through with all
requirements for submission to the IRB. All IRB approvals are required to be
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documented in Oncore, and all associated regulatory documentation (signed
applications, IRB approval letters and IRB approved consent forms, etc.) are
to be saved in the appropriate study folder in the e-binders directory at
J:\ebinders.
Oncore is the Cancer Center’s mechanism for required submission and review
of materials requiring IRB review as well as items requiring review by the
Scientific Review and Protocol Monitoring Committees. If you are not
currently reporting the necessary research activities, such as patient accrual,
changes in procedure, adverse events and continuing reviews in Oncore,
please contact Jeryl Madden, Oncore Coordinator, at 745-6964 for direction.
Sincerely,

Paul Jacobsen, PhD
Chair,Behavioral Subcommittee
Scientific Review Committee
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Appendix E: USF IRB Approval

January 28, 2011
Gloria Guess
College of Nursing

RE: Exempt Certification for IRB#: Pro00003031
Title: Correlation of Cancer-Related Fatigue and Depression: a
Pilot Study
Dear Gloria Guess:
On 1/27/2011, the Institutional Review Board (IRB) determined that your research
meets USF requirements and Federal Exemption criteria as outlined in the federal
regulations at 45CFR46.101(b):
(2) Research involving the use of educational tests (cognitive, diagnostic, aptitude,
achievement), survey procedures, interview procedures or observation of public
behavior, unless:
(i) information obtained is recorded in such a manner that human subjects can be
identified, directly or through identifiers linked to the subjects; and (ii) any disclosure
of the human subjects' responses outside the research could reasonably place the
subjects at risk of criminal or civil liability or be damaging to the subjects' financial
standing, employability, or reputation.
As the principal investigator for this study, it is your responsibility to ensure that this
research is conducted as outlined in your application and consistent with the ethical
principles outlined in the Belmont Report and with USF IRB policies and procedures.
Please note that changes to this protocol may disqualify it from exempt status. Please
note that you are responsible for notifying the IRB prior to implementing any changes
to the currently approved protocol.
The Institutional Review Board will maintain your exemption application for a
period of five years from the date of this letter or for three years after a Final
Progress Report is received, whichever is longer. If you wish to continue this
protocol beyond five years, you will need to submit a continuing review application
at least 60 days prior to the exemption expiration date. Should you complete this
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study prior to the end of the five-year period, you must submit a request to close the
study.
We appreciate your dedication to the ethical conduct of human subject research
at the University of South Florida and your continued commitment to human
research protections. If you have any questions regarding this matter, please
call 813-974-5638.
Sincerely,

John Schinka, PhD, Chairperson
USF Institutional Review Board
Cc: Various Menzel, CCRP, USF IRB Professional Staff
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Appendix F: Informed Consent

Informed Consent to Participate in Research
Information to Consider Before Taking Part in this Research Study
IRB Study # _______3031_______
You are being asked to take part in a research study. Research studies include only people who
choose to take part. This document is called an informed consent form. Please read this
information carefully and take your time making your decision. Ask the researcher or study staff
to discuss this consent form with you, please ask him/her to explain any words or information
you do not clearly understand. We encourage you to talk with your family and friends before
you decide to take part in this research study. The nature of the study, risks, inconveniences,
discomforts, and other important information about the study are listed below.

We are asking you to take part in a research study called: Correlation of Cancer-Related
Fatigue and Depression
The person who is in charge of this research study is Gloria Michelle Guess. This person is called
the Principal Investigator. However, other research staff may be involved and can act on behalf
of the person in charge. She is being guided in this research by Dr. Susan McMillan.
The research will be conducted at Moffitt Cancer Center Infusion Center.

Purpose of the study
The purpose of this study is to:
• The purpose of this study is to determine whether or not a relationship exists
between cancer-related fatigue and depression in cancer patient’s receiving
chemotherapy.
• This study is being done as part of a thesis.

Study Procedures
If you take part in this study, you will be asked to

•

Complete three brief questionnaires, while you are at the infusion center receiving
your chemotherapy. The time it will take to complete these questionnaires should
be less than 30 minutes. You will only be asked to complete the questionnaires
during one visit.

•

One questionnaire will ask basic demographic information such as age, gender,
diagnosis, and number of chemotherapy treatments completed.
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•
•

The second questionnaire is a seven question, written depression scale, used to assess
how you are feeling.
The third questionnaire is a thirty question written fatigue scale to assess if you may be
having any symptoms of fatigue.

Total Number of Participants
About 60 individuals will take part in this study at USF.

Alternatives
You do not have to participate in this research study.

Benefits
The potential benefits of participating in this research study include increasing our knowledge of
cancer-related fatigue and depression in cancer patients on chemotherapy.

Risks or Discomfort
This research is considered to be minimal risk. That means that the risks associated with this
study are the same as what you face every day. There are no known additional risks to those
who take part in this study.

Compensation
You will receive no payment or other compensation for taking part in this study.

Cost
There will be no additional costs to you as a result of being in this study. However,
routine medical care for your condition (care you would have received whether or not
you were in this study) will be charged to you or your insurance company. You may
wish to contact your insurance company to discuss this further.

Privacy and Confidentiality
Other than meeting you in person during the data collection process I will not be recording any
identifiers or liking at any of your medical records or other documentation containing your
Protected Health Information. Moffitt Cancer Center will not be releasing any of your identifiers
to me to conduct this research.

We will keep your study records private and confidential. Certain people may need to
see your study records. By law, anyone who looks at your records must keep them
completely confidential. The only people who will be allowed to see these records are:
• The research team, including the Principal Investigator and faculty advisor.
• Certain government and university people who need to know more about the
study. For example, individuals who provide oversight on this study may need to
look at your records. This is done to make sure that we are doing the study in the
right way. They also need to make sure that we are protecting your rights and
your safety.
• Any agency of the federal, state, or local government that regulates this research.
This includes the Department of Health and Human Services (DHHS) and the
Office for Human Research Protection (OHRP).
• The USF Institutional Review Board (IRB) and its related staff, who have
oversight responsibilities for this study, staff in the USF Office of Research and
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Innovation, USF Division of Research Integrity and Compliance, and other USF
offices who oversee this research.
We may publish what we learn from this study. If we do, we will not include your name.
We will not publish anything that would let people know who you are.

Voluntary Participation / Withdrawal
You should only take part in this study if you want to volunteer. You should not feel that
there is any pressure to take part in the study. You are free to participate in this research
or withdraw at any time. There will be no penalty or loss of benefits you are entitled to
receive if you stop taking part in this study. The decision not to participate/terminate
participation will have no effect on medical treatment the participant is receiving.

You can get the answers to your questions, concerns, or complaints
If you have any questions, concerns or complaints about this study, or experience an
adverse event or unanticipated problem, call Gloria Michelle Guess at 727-359-9312.
If you have questions about your rights as a participant in this study, general questions, or
have complaints, concerns or issues you want to discuss with someone outside the
research, call the USF IRB at (813) 974-5638. Moffitt Cancer Center Division of
Research Integrity and Compliance at (813) 632-1869.
I verbally agree to participate and I have been given a copy of this document.

45

